Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by GrahamBon Nov 29, 2024 6:48pm
48 Views
Post# 36338483

Q3 Financials Out-first pass

Q3 Financials Out-first pass
Took a Quick Look at the financials , and starting with the Balance sheet....
Source -sedar.com

Looking at the balance sheet first, looks like significant deterioration 
Current Assets-Declined significantly from $1,636,787 in December 2023 to $518,901 in September 2024.
Major decrease in cash and cash equivalents ($1,294,346 to $110,693) and accounts receivable ($285,499 to $212,719).
 
Total Assets-Dropped significantly from $1,883,385 in 2023 to $718,065 in 2024.
Current LiabilitiesIncreased from $1,396,693 to $1,863,761, driven by higher accounts payable and accrued liabilities.
Total Liabilities:Increased from $1,693,679 to $3,179,443.
Shareholders’ Equity (Deficiency):The deficit worsened significantly, from ($189,706) in 2023 to ($2,461,378) in 2024.
 
 
What does it mean:
The company has a severe liquidity issue, indicated by the substantial reduction in current assets and cash, combined with rising current liabilities.
The shareholders' equity is now in a significant deficit
 
The increase in liabilities, particularly in accounts payable and accrued liabilities, highlights mounting financial obligations.


Again, and as always
All imo
for fun anf learning
Not to invest based on what you read here-from anyone 
Do your own due diligence
I don't own shares and no intention of buying now
Need sales
need profir
lets look at p&L and cash flow what?
<< Previous
Bullboard Posts
Next >>